Last
Update:
August 10, 2008
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
XVII International AIDS Conference
|
POSTER
ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in
antiretroviral-naïve patients
E Arathoon, E Baraldi, PL Lim, et al
PDF Poster
POSTER
ARTEMIS: Week 48 safety and efficacy of darunavir/r by gender, age and race
J Andrade-Villanueva, G Herrera, P Chiliade, et al
PDF Poster
POSTER
Comparable in-vitro susceptibility and virologic outcome to darunavir in
patients infected
with subtype B and subtype non-B HIV isolates participating in the ARTEMIS
Phase III trial
I Dierynck, S De Meyer, E Lathouwers, et al
PDF Poster
POSTER
Pharmacokinetic interaction between darunavir in combination with low-dose
ritonavir
and carbamazepine
VJ Sekar, F Tomaka, L Lavreys, et al
PDF Poster
POSTER
Dose selection and pharmacokinetics-pharmacodynamics of darunavir
coadministered with low-dose ritonavir
in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected
children and adolescents
V Sekar, T Van de Casteele, B Van Baelen, et al
PDF Poster
CONFERENCE POWERPOINT
POSTER
Effects of nucleoside analogues versus ritonavir boosted protease inhibitors
on lipid levels – analysis of 12 clinical
trials in 4231 antiretroviral naïve patients
A Hill, B Gazzard
PowerPoint
Poster
2008 International
HIV Drug Resistance Workshop
|
-
POSTER
Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN
trial
A Hill, A-G Marcelin, V Calvez, et al
PDF Poster
-
POSTER
Comparable in-vitro susceptibility and virological outcome to
darunavir in patients infected
with subtype B and non-subtype B HIV isolates participating in the
ARTEMIS Phase III trial
I Dierynck, SDe Meyer, E Lathouwers, et al
PDF Poster
-
POSTER
Phenotypic and genotypic determinants of resistance to darunavir:
analysis of data from
treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and
DUET-2
S De Meyer, I Dierynck, E Lathouwers, et al
PDF Poster
14th Annual BHIVA
Conference
|
9th International
Workshop on Clinical Pharmacology of HIV
|
A WEEK IN REVIEW FEATURED REPORT
POWERPOINT PRESENTATION
Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose
Ritonavir (DRV/r) in
Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in
a Substudy of the
GRACE (Gender, Race, and Clinical Experience) Study
V Sekar, R Ryan, D Schaible, et al
Slide Presentation
POSTER
Effect of extrinsic and intrinsic factors on the pharmacokinetics of
darunavir/ritonavir in
HIV-1-infected patients: results of a randomized, controlled, Phase III
study (ARTEMIS)
V Sekar, C Vanden Abeele, B Van Baelen, et al
PDF Poster
Cocktail study to investigate the in-vivo drug interaction potential of
darunavir coadministered
with low-dose ritonavir (DRV/r; RTV) on cytochrome P450 enzymes 2D6, 2C9
and 2C19
V Sekar, S Spinosa-Guzman, P Meyvisch, et al
PDF Poster
POSTER
The pharmacokinetic profile of darunavir with low dose ritonavir in
multiple-dose regimens
over 120 hours
M Boffito, G Moyle, A hill, et al
PDF Poster
POSTER
Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the
ARTEMIS study
V Sekar, C Vanden Abeele, B Van Baelen, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED REPORT
POSTER
Efficacy of DRV/r in the randomised, controlled, Phase III
ARTEMIS trial in
treatment-naïve, HIV-1-infected patients is independent of HIV-1 subtype
I Dierynck, S De Meyer,E Lathouwers, et al
PDF Poster
-
POSTER
Update on the prevalence of the 2007 darunavir
resistance-associated mutations in
samples received for routine clinical resistance testing
E Lathouwers, S De Meyer, I Dierynck, et al
PDF Poster
-
POSTER
Identification of mutations predictive of a diminished response
to darunavir/ritonavir: analysis
of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and
DUET-2
S De Meyer, I Dierynck, E Lathouwers, et al
PDF Poster
-
POWERPOINT PRESENTATION
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a
Regimen-Based
Resistance Interpretation
JM Schapiro, J Vingerhoets, S Nijs, et al
Slide Presentation
-
POSTER
Inhibitory
Quotient as a Predictor of Virological Response to Darunavir-based Salvage
Regimens
J Molto, J Santos N Perez-Alvarez, et al
PDF Poster
Abstract
-
POSTER
Characterization of Virologic Failures on Darunavir/Ritonavir in the
Randomized, Controlled,
Phase III TITAN Trial in Treatment-experienced Patients
S De Meyer, E
Lathouwers, I Dierynck, et al
PDF Poster
-
Safety and
Efficacy of Darunavir Co-administered with Low-dose Ritonavir in
Treatment-experienced Children and
Adolescents at Week 24
R Bologna, S Rugina, P Cahn, et al
-
POSTER
Pharmacokinetic/Pharmacodynamic Analyses of Once-daily Darunaviriin
the ARTEMIS Study
V Sekar, C Vanden Abeele, B Van Baelen, et al
PDF Poster
Abstract
-
Tolerability of Darunavir/ritonavir Versus Lopinavir/ritonavir in
Lopinavir/ritonavir-Naïve,
Treatment-Experienced, Hepatitis B or C Co-infected Patients in TITAN
D Jayaweera, E De Paepe, JM Mrus, et al
PDF Poster
-
POSTER
Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose
Ritonavir in
Individuals with Impaired Hepatic Function
F Tomaka, RMW Hoetelmans, S Spinosa-Guzman, et al
PDF Poster
-
POSTER
Tolerability of once-daily darunavir/r versus lopinavir/r in treatment-naïve
patients
coinfected withhepatitis B and/or C in the ARTEMIS trial
R Ortiz, J Fourie, J Andrade-Villanueva, et al
PDF Poster\
|
XVII
International AIDS Conference
Conference
Archives - A
